The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease

Nutrition Research

Volumn 36, Issue 12, 2016, Pages 1305-1315

  Grizzanti, John ^a   Lee, Hyoung Gon ^b   Camins, Antoni ^c   Pallas, Merce ^c   Casadesus, Gemma ^a  

^a KENT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer disease; Amylin; Diabetes; Insulin; Leptin; Obesity

Indexed keywords

AMYLIN; INSULIN; INSULINASE; LEPTIN; PRAMLINTIDE; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; APOPTOSIS; CALCIUM TRANSPORT; DISEASE ASSOCIATION; ENZYME INHIBITION; GLYCEMIC CONTROL; HORMONE SYNTHESIS; HUMAN; HYPERLEPTINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIFESTYLE; LOSS OF APPETITE; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RISK REDUCTION; SEDENTARY LIFESTYLE; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; COGNITION; COGNITIVE DEFECT; METABOLISM;

AGING; ALZHEIMER DISEASE; COGNITION; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; ISLET AMYLOID POLYPEPTIDE; LEPTIN; OBESITY;

EID: 85006765693     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2016.11.002     Document Type: Review

References (162)

1. [1] Fryar, C.D., Carroll, M.D., Ogden, C.L., Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, 1960–1962 Through 2011–2012. 2014, C.f.D. Control, Editor, 1–6.
2. [2] Yang, L., Colditz, G.A., Prevalence of Overweight and Obesity in the United States, 2007-2012. JAMA Intern Med 175:8 (2015), 1412–1413.
3. [3] Ineichen, B., Fast food nation: What the All-American meal is doing to the world. J Adv Nurs, 36(2), 2001, 322.
4. [4] Brown, W.V., Carson, J.A.S., Johnson, R.K., Kris-Etherton, P., JCL Roundtable: Fast Food and the American Diet. J Clin Lipidol 9:1 (2015), 3–10.
5. [5] Sacks, F.M., Bray, G.A., Carey, V.J., Smith, S.R., Ryan, D.H., Anton, S.D., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360:9 (2009), 859–873.
6. [6] Lanningham‐Foster, L., Nysse, L.J., Levine, J.A., Labor saved, calories lost: the energetic impact of domestic labor‐saving devices. Obes Res 11:10 (2003), 1178–1181.
7. [7] Dietz, W.H., Baur, L.A., Hall, K., Puhl, R.M., Taveras, E.M., Uauy, R., et al. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet 385:9986 (2015), 2521–2533.
8. [8] Puhl, R.M., Liu, S., A national survey of public views about the classification of obesity as a disease. Obesity 23:6 (2015), 1288–1295.
9. [9] Antonelli, J.A., Maalouf, N.M., Pearle, M.S., Lotan, Y., Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur Urol 66:4 (2014), 724–729.
10. [10] Aguilar, M., Bhuket, T., Torres, S., Liu, B., Wong, R.J., Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 313:19 (2015), 1973–1974.
11. [11] Must, A., Spadano, J., Coakley, E.H., Field, A.E., Colditz, G., Dietz, W.H., The disease burden associated with overweight and obesity. JAMA 282:16 (1999), 1523–1529.
12. [12] Ogden, C.L., Carroll, M.D., McDowell, M.A., Flegal, K.M., Obesity among adults in the United States-no statistically significant change since 2003-2004. NCHS Data Brief(1), 2007, 1–8.
13. [13] Ashrafian, H., Harling, L., Darzi, A., Athanasiou, T., Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?. Metab Brain Dis 28:3 (2013), 341–353.
14. [14] Hedström, A.K., Olsson, T., Alfredsson, L., High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler J 18:9 (2012), 1334–1336.
15. [15] Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P., Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:20 (2000), 1430–1438.
16. [16] Langer-Gould, A., Brara, S.M., Beaber, B.E., Koebnick, C., Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 80:6 (2013), 548–552.
17. [17] Gustafson, D., Bäckman, K., Waern, M., Östling, S., Guo, X., Zandi, P., et al. Adiposity indicators and dementia over 32 years in Sweden. Neurology 73:19 (2009), 1559–1566.
18. [18] Whitmer, R., Gustafson, D., Barrett-Connor, E., Haan, M., Gunderson, E., Yaffe, K., Central obesity and increased risk of dementia more than three decades later. Neurology 71:14 (2008), 1057–1064.
19. [19] Whitmer, R.A., Gunderson, E.P., Barrett-Connor, E., Quesenberry, C.P., Yaffe, K., Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330:7504 (2005), 1360–1365.
20. [20] Whitmer, R.A., Gunderson, E.P., Quesenberry, C.P., Zhou, J., Yaffe, K., Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 4:2 (2007), 103–109.
21. [21] Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62:10 (2005), 1556–1560.
22. [22] Hetzel, L., 65 Years and Over Population: 2000: Census 2000 Brief. 2008, DIANE Publishing.
23. [23] Meyer, J., Age: 2000: census 2000 brief. 2008, DIANE Publishing.
24. [24] Floyd, R.A., Antioxidants, oxidative stress, and degenerative neurological disorders. Exp Biol Med 222:3 (1999), 236–245.
25. [25] Floyd, R.A., Carney, J.M., Age influence on oxidative events during brain ischemia/reperfusion. Arch Gerontol Geriatr 12:2 (1991), 155–177.
26. [26] Floyd, R.A., Carney, J.M., Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 32:S1 (1992), S22–S27.
27. [27] Yu, B.P., Cellular defenses against damage from reactive oxygen species. Physiol Rev 74:1 (1994), 139–162.
28. [28] Fang, Y.-Z., Yang, S., Wu, G., Free radicals, antioxidants, and nutrition. Nutrition 18:10 (2002), 872–879.
29. [29] Gilgun-Sherki, Y., Melamed, E., Offen, D., Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40:8 (2001), 959–975.
30. [30] Floyd, R.A., Hensley, K., Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23:5 (2002), 795–807.
31. [31] Evans, J.L., Goldfine, I.D., Maddux, B.A., Grodsky, G.M., Are Oxidative Stress− Activated Signaling Pathways Mediators of Insulin Resistance and β-Cell Dysfunction?. Diabetes 52:1 (2003), 1–8.
32. [32] Guo, Z., Jiang, H., Xu, X., Duan, W., Mattson, M.P., Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J Biol Chem 283:3 (2008), 1754–1763.
33. [33] Anello, M., Lupi, R., Spampinato, D., Piro, S., Masini, M., Boggi, U., et al. Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 48:2 (2005), 282–289.
34. [34] Holmström, M.H., Iglesias-Gutierrez, E., Zierath, J.R., Garcia-Roves, P.M., Tissue-specific control of mitochondrial respiration in obesity-related insulin resistance and diabetes. Am J Physiol Endocrinol Metab 302:6 (2012), E731–E739.
35. [35] Butterfield, D.A., Di Domenico, F., Barone, E., Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta (BBA) - Mol Basis Dis 1842:9 (2014), 1693–1706.
36. [36] Zraika, S., Hull, R., Udayasankar, J., Aston-Mourney, K., Subramanian, S., Kisilevsky, R., et al. Oxidative stress is induced by islet amyloid formation and time-dependently mediates amyloid-induced beta cell apoptosis. Diabetologia 52:4 (2009), 626–635.
37. [37] Inestrosa, N., Alvarez, A., Godoy, J., Reyes, A., De Ferrari, G., Acetylcholinesterase–amyloid‐β‐peptide interaction and Wnt signaling involvement in Aβ neurotoxicity. Acta Neurol Scand 102:s176 (2000), 53–59.
38. [38] Fealy, C.E., Mulya, A., Lai, N., Kirwan, J.P., Exercise training decreases activation of the mitochondrial fission protein dynamin-related protein-1 in insulin-resistant human skeletal muscle. J Appl Physiol 117:3 (2014), 239–245.
39. [39] Jiménez-Palomares, M., Ramos-Rodríguez, J.J., López-Acosta, J.F., Pacheco-Herrero, M., Lechuga-Sancho, A.M., Perdomo, G., et al. Increased Aβ production prompts the onset of glucose intolerance and insulin resistance. Am J Physiol Endocrinol Metab 302:11 (2012), E1373–E1380.
40. [40] Kawahara, M., Kuroda, Y., Arispe, N., Rojas, E., Alzheimer's β-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275:19 (2000), 14077–14083.
41. [41] Wellen, K.E., Hotamisligil, G.S., Inflammation, stress, and diabetes. J Clin Invest 115:5 (2005), 1111–1119.
42. [42] Scherer, P.E., Adipose tissue from lipid storage compartment to endocrine organ. Diabetes 55:6 (2006), 1537–1545.
43. [43] Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J Clin Invest 116:7 (2006), 1793–1801.
44. [44] Posey, K.A., Clegg, D.J., Printz, R.L., Byun, J., Morton, G.J., Vivekanandan-Giri, A., et al. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296:5 (2009), E1003–E1012.
45. [45] Verchere, C.B., D'Alessio, D.A., Palmiter, R.D., Weir, G.C., Bonner-Weir, S., Baskin, D.G., et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci 93:8 (1996), 3492–3496.
46. [46] Höppener, J., Oosterwijk, C., Nieuwenhuis, M., Posthuma, G., Thijssen, J., Vroom, T.M., et al. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:4 (1999), 427–434.
47. [47] LaFerla, F.M., Oddo, S., Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol Med 11:4 (2005), 170–176.
48. [48] Alzheimer's, A., 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11:3 (2015), 332–384.
49. [49] Förstl, H., Kurz, A., Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249:6 (1999), 288–290.
50. [50] Glenner, G.G., Wong, C.W., Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:3 (1984), 1131–1135.
51. [51] Moreira, P.I., Duarte, A.I., Santos, M.S., Rego, A.C., Oliveira, C.R., An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16:4 (2009), 741–761.
52. [52] Zhu, X., Perry, G., Moreira, P.I., Aliev, G., Cash, A.D., Hirai, K., et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9:2 (2006), 147–153.
53. [53] Clark, T.A., Lee, H.P., Rolston, R.K., Zhu, X., Marlatt, M.W., Castellani, R.J., et al. Oxidative stress and its implications for future treatments and management of Alzheimer disease. Int J Biomed Sci, 6(3), 2010, 225.
54. [54] Wenk, G.L., Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry, 67, 2006, 3.
55. [55] Buchman, A.S., Wilson, R.S., Bienias, J.L., Shah, R.C., Evans, D.A., Bennett, D.A., Change in body mass index and risk of incident Alzheimer disease. Neurology 65:6 (2005), 892–897.
56. [56] Fitzpatrick, A.L., Kuller, L.H., Lopez, O.L., Diehr, P., O'Meara, E.S., Longstreth, W., et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 66:3 (2009), 336–342.
57. [57] Luchsinger, J.A., Cheng, D., Tang, M.X., Schupf, N., Mayeux, R., Central obesity in the elderly is related to late onset Alzheimer's disease. Alzheimer Dis Assoc Disord, 26(2), 2012, 101.
58. [58] Oskarsson, M.E., Paulsson, J.F., Schultz, S.W., Ingelsson, M., Westermark, P., Westermark, G.T., In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol 185:3 (2015), 834–846.
59. [59] Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Wands, J.R., de la Monte, S.M., Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8:3 (2005), 247–268.
60. [60] Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K.P., Stucky, A., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:4 (2012), 1316–1338.
61. [61] Cook, D.G., Leverenz, J.B., McMillan, P.J., Kulstad, J.J., Ericksen, S., Roth, R.A., et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele. Am J Pathol 162:1 (2003), 313–319.
62. [62] Johnson, K., O'Brien, T., Jordan, K., Westermark, P., Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol, 135(2), 1989, 245.
63. [63] Johnson, K.H., O'Brien, T.D., Betsholtz, C., Westermark, P., Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 321:8 (1989), 513–518.
64. [64] Kimura, R., MacTavish, D., Yang, J., Westaway, D., Jhamandas, J.H., Pramlintide Antagonizes Beta Amyloid (Aβ)-and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation. Mol Neurobiol, 2016, 1–7.
65. [65] Storlien, L.H., Jenkins, A.B., Chisholm, D.J., Pascoe, W.S., Khouri, S., Kraegen, E.W., Influence of dietary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid. Diabetes 40:2 (1991), 280–289.
66. [66] Kraegen, E.W., Clark, P.W., Jenkins, A.B., Daley, E.A., Chisholm, D.J., Storlien, L.H., Development of muscle insulin resistance after liver insulin resistance in high-fat–fed rats. Diabetes 40:11 (1991), 1397–1403.
67. [67] Camhi, S.M., Bray, G.A., Bouchard, C., Greenway, F.L., Johnson, W.D., Newton, R.L., et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity 19:2 (2011), 402–408.
68. [68] Ryan, A.S., Insulin resistance with aging. Sports Med 30:5 (2000), 327–346.
69. [69] Boden, G., Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:1 (1997), 3–10.
70. [70] Petersen, K.F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D.L., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:5622 (2003), 1140–1142.
71. [71] Kahn, S.E., Hull, R.L., Utzschneider, K.M., Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:7121 (2006), 840–846.
72. [72] Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci 100:7 (2003), 4162–4167.
73. [73] Banks, W.A., Jaspan, J.B., Huang, W., Kastin, A.J., Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18:9 (1997), 1423–1429.
74. [74] Banks, W.A., Jaspan, J.B., Kastin, A.J., Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18:8 (1997), 1257–1262.
75. [75] Baura, G.D., Foster, D.M., Porte, D. Jr., Kahn, S.E., Bergman, R.N., Cobelli, C., et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 92:4 (1993), 1824–1830.
76. [76] Wallum, B., Taborsky, G. Jr., Porte, D. Jr., Figlewicz, D., Jacobson, L., Beard, J., et al. Cerebrospinal Fluid Insulin Levels Increase During Intravenous Insulin Infusions in Man*. J Clin Endocrinol Metab 64:1 (1987), 190–194.
77. [77] Hoyer, S., Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105:4-5 (1998), 415–422.
78. [78] Hoyer, S., Nitsch, R., Oesterreich, K., Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 3:1 (1991), 1–14.
79. [79] Plum, L., Schubert, M., Brüning, J.C., The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 16:2 (2005), 59–65.
80. [80] Steen, E., Terry, B.M., Rivera, E.J., Cannon, J.L., Neely, T.R., Tavares, R., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease–is this type 3 diabetes?. J Alzheimers Dis 7:1 (2005), 63–80.
81. [81] Jheng, H.-F., Tsai, P.-J., Guo, S.-M., Kuo, L.-H., Chang, C.-S., Su, I.-J., et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol 32:2 (2012), 309–319.
82. [82] Fain, J.N., Madan, A.K., Hiler, M.L., Cheema, P., Bahouth, S.W., Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145:5 (2004), 2273–2282.
83. [83] Reaven, G.M., Hollenbeck, C., Jeng, C.-Y., Wu, M.S., Chen, Y.-D.I., Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:8 (1988), 1020–1024.
84. [84] Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:12 (2003), 1821–1830.
85. [85] Dandona, P., Aljada, A., Bandyopadhyay, A., Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:1 (2004), 4–7.
86. [86] Moraes, J.C., Coope, A., Morari, J., Cintra, D.E., Roman, E.A., Pauli, J.R., et al. High-fat diet induces apoptosis of hypothalamic neurons. PLoS One, 4(4), 2009, e5045.
87. [87] Duckworth, W.C., Bennett, R.G., Hamel, F.G., Insulin degradation: progress and potential 1. Endocr Rev 19:5 (1998), 608–624.
88. [88] Goldfine, I.D., Williams, J.A., Bailey, A.C., Wong, K., Iwamoto, Y., Yokono, K., et al. Degradation of insulin by isolated mouse pancreatic acini: evidence for cell surface protease activity. Diabetes 33:1 (1984), 64–72.
89. [89] Seta, K.A., Roth, R.A., Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem Biophys Res Commun 231:1 (1997), 167–171.
90. [90] Vekrellis, K., Ye, Z., Qiu, W.Q., Walsh, D., Hartley, D., Chesneau, V., et al. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20:5 (2000), 1657–1665.
91. [91] Lynch, J.A., George, A.M., Eisenhauer, P.B., Conn, K., Gao, W., Carreras, I., et al. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. J Neurosci Res 83:7 (2006), 1262–1270.
92. [92] Bennett, R.G., Duckworth, W.C., Hamel, F.G., Degradation of amylin by insulin-degrading enzyme. J Biol Chem 275:47 (2000), 36621–36625.
93. [93] Kurochkin, I.V., Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem Sci 26:7 (2001), 421–425.
94. [94] Karamohamed, S., Demissie, S., Volcjak, J., Liu, C., Heard-Costa, N., Liu, J., et al. Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes 52:6 (2003), 1562–1567.
95. [95] Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:7130 (2007), 881–885.
96. [96] Marlowe, L., Peila, R., Benke, K.S., Hardy, J., White, L.R., Launer, L.J., et al. Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk. Neurodegener Dis 3:6 (2007), 320–326.
97. [97] Giordano, V., Peluso, G., Iannuccelli, M., Benatti, P., Nicolai, R., Calvani, M., Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. Neurochem Res 32:4-5 (2007), 555–567.
98. [98] Salameh, T.S., Bullock, K.M., Hujoel, I.A., Niehoff, M.L., Wolden-Hanson, T., Kim, J., et al. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J Alzheimers Dis 47:3 (2015), 715–728.
99. [99] Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:1 (2012), 29–38.
100. [100] Rosenbloom, M.H., Barclay, T.R., Pyle, M., Owens, B.L., Cagan, A.B., Anderson, C.P., et al. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild–moderate Alzheimer's disease. CNS Drugs 28:12 (2014), 1185–1189.
101. [101] Brennan, A.M., Mantzoros, C.S., Drug Insight: the role of leptin in human physiology and pathophysiology—emerging clinical applications. Nat Rev Endocrinol 2:6 (2006), 318–327.
102. [102] Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:5 (1996), 292–295.
103. [103] Myers, M.G., Cowley, M.A., Münzberg, H., Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70 (2008), 537–556.
104. [104] Bjørbæk, C., Elmquist, J.K., Michl, P., Ahima, R.S., Van Bueren, A., McCall, A.L., et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 139:8 (1998), 3485–3491.
105. [105] Elmquist, J.K., Bjørbæk, C., Ahima, R.S., Flier, J.S., Saper, C.B., Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 395:4 (1998), 535–547.
106. [106] Fei, H., Okano, H.J., Li, C., Lee, G.-H., Zhao, C., Darnell, R., et al. Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues. Proc Natl Acad Sci 94:13 (1997), 7001–7005.
107. [107] Gabriely, I., Ma, X.H., Yang, X.M., Rossetti, L., Barzilai, N., Leptin resistance during aging is independent of fat mass. Diabetes 51:4 (2002), 1016–1021.
108. [108] Münzberg, H., Differential leptin access into the brain—a hierarchical organization of hypothalamic leptin target sites?. Physiol Behav 94:5 (2008), 664–669.
109. [109] Couturier, C., Sarkis, C., Séron, K., Belouzard, S., Chen, P., Lenain, A., et al. Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity. Proc Natl Acad Sci 104:49 (2007), 19476–19481.
110. [110] Tezapsidis, N., Johnston, J.M., Smith, M.A., Ashford, J.W., Casadesus, G., Robakis, N.K., et al. Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis 16:4 (2009), 731–740.
111. [111] Burguera, B., Couce, M.E., Long, J., Lamsam, J., Laakso, K., Jensen, M.D., et al. The long form of the leptin receptor (OB-Rb) is widely expressed in the human brain. Neuroendocrinology 71:3 (2000), 187–195.
112. [112] O'Malley, D., MacDonald, N., Mizielinska, S., Connolly, C.N., Irving, A.J., Harvey, J., Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol Cell Neurosci 35:4 (2007), 559–572.
113. [113] Valerio, A., Ghisi, V., Dossena, M., Tonello, C., Giordano, A., Frontini, A., et al. Leptin increases axonal growth cone size in developing mouse cortical neurons by convergent signals inactivating glycogen synthase kinase-3β. J Biol Chem 281:18 (2006), 12950–12958.
114. [114] Garza, J.C., Guo, M., Zhang, W., Lu, X.-Y., Leptin increases adult hippocampal neurogenesis in vivo and in vitro. J Biol Chem 283:26 (2008), 18238–18247.
115. [115] Bouret, S.G., Draper, S.J., Simerly, R.B., Trophic action of leptin on hypothalamic neurons that regulate feeding. Science 304:5667 (2004), 108–110.
116. [116] Zhang, F., Chen, J., Leptin protects hippocampal CA1 neurons against ischemic injury. J Neurochem 107:2 (2008), 578–587.
117. [117] Zhang, F., Wang, S., Signore, A.P., Chen, J., Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke 38:8 (2007), 2329–2336.
118. [118] Shanley, L.J., O'Malley, D., Irving, A., Ashford, M., Harvey, J., Leptin inhibits epileptiform‐like activity in rat hippocampal neurones via PI 3‐kinase‐driven activation of BK channels. J Physiol 545:3 (2002), 933–944.
119. [119] Doherty, G., Oldreive, C., Harvey, J., Neuroprotective actions of leptin on central and peripheral neurons in vitro. Neuroscience 154:4 (2008), 1297–1307.
120. [120] Valerio, A., Dossena, M., Bertolotti, P., Boroni, F., Sarnico, I., Faraco, G., et al. Leptin Is Induced in the Ischemic Cerebral Cortex and Exerts Neuroprotection Through NF-κB/c-Rel–Dependent Transcription. Stroke 40:2 (2009), 610–617.
121. [121] Weng, Z., Signore, A.P., Gao, Y., Wang, S., Zhang, F., Hastings, T., et al. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J Biol Chem 282:47 (2007), 34479–34491.
122. [122] Shanley, L.J., Irving, A.J., Harvey, J., Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci, 21(24), 2001, RC186.
123. [123] Lieb, W., Beiser, A.S., Vasan, R.S., Tan, Z.S., Au, R., Harris, T.B., et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 302:23 (2009), 2565–2572.
124. [124] Holden, K.F., Lindquist, K., Tylavsky, F.A., Rosano, C., Harris, T.B., Yaffe, K., Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol Aging 30:9 (2009), 1483–1489.
125. [125] Bigalke, B., Schreitmüller, B., Sopova, K., Paul, A., Stransky, E., Gawaz, M., et al. Adipocytokines and CD34+ progenitor cells in Alzheimer's disease. PLoS One, 6(5), 2011, e20286.
126. [126] Bonda, D.J., Stone, J.G., Torres, S.L., Siedlak, S.L., Perry, G., Kryscio, R., et al. Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. J Neurochem 128:1 (2014), 162–172.
127. [127] Greco, S.J., Sarkar, S., Casadesus, G., Zhu, X., Smith, M.A., Ashford, J.W., et al. Leptin inhibits glycogen synthase kinase-3β to prevent tau phosphorylation in neuronal cells. Neurosci Lett 455:3 (2009), 191–194.
128. [128] Greco, S.J., Sarkar, S., Johnston, J.M., Tezapsidis, N., Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 380:1 (2009), 98–104.
129. [129] Greco, S.J., Sarkar, S., Johnston, J.M., Zhu, X., Su, B., Casadesus, G., et al. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun 376:3 (2008), 536–541.
130. [130] Halagappa, V.K.M., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R.G., LaFerla, F.M., et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis 26:1 (2007), 212–220.
131. [131] Mouton, P.R., Chachich, M.E., Quigley, C., Spangler, E., Ingram, D.K., Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS1 mice. Neurosci Lett 464:3 (2009), 184–187.
132. [132] Patel, N.V., Gordon, M.N., Connor, K.E., Good, R.A., Engelman, R.W., Mason, J., et al. Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models. Neurobiol Aging 26:7 (2005), 995–1000.
133. [133] Van Der Auwera, I., Wera, S., Van Leuven, F., Henderson, S.T., A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab, 2(1), 2005, 1.
134. [134] Wang, J., Ho, L., Qin, W., Rocher, A.B., Seror, I., Humala, N., et al. Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 19:6 (2005), 659–661.
135. [135] Greco, S.J., Bryan, K.J., Sarkar, S., Zhu, X., Smith, M.A., Ashford, J.W., et al. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 19:4 (2010), 1155–1167.
136. [136] Roth, J.D., Roland, B.L., Cole, R.L., Trevaskis, J.L., Weyer, C., Koda, J.E., et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci 105:20 (2008), 7257–7262.
137. [137] Trevaskis, J.L., Coffey, T., Cole, R., Lei, C., Wittmer, C., Walsh, B., et al. Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149:11 (2008), 5679–5687.
138. [138] Mollet, A., Lutz, T., Meier, S., Riediger, T., Rushing, P., Scharrer, E., Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Phys Regul Integr Comp Phys 281:5 (2001), R1442–R1448.
139. [139] Boyle, C.N., Rossier, M.M., Lutz, T.A., Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin. Physiol Behav 104:1 (2011), 20–28.
140. [140] Lutz, T.A., Amylinergic control of food intake. Physiol Behav 89:4 (2006), 465–471.
141. [141] Hwang, J.J., Chan, J.L., Ntali, G., Malkova, D., Mantzoros, C.S., Leptin does not directly regulate the pancreatic hormones amylin and pancreatic polypeptide Interventional studies in humans. Diabetes Care 31:5 (2008), 945–951.
142. [142] Gedulin, B.R., Rink, T.J., Young, A.A., Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:1 (1997), 67–70.
143. [143] Young, A., Inhibition of gastric emptying. Adv Pharmacol 52 (2005), 99–121.
144. [144] Ratner, R., Dickey, R., Fineman, M., Maggs, D., Shen, L., Strobel, S., et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial. Diabet Med 21:11 (2004), 1204–1212.
145. [145] Kimura, R., MacTavish, D., Yang, J., Westaway, D., Jhamandas, J.H., Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J Neurosci 32:48 (2012), 17401–17406.
146. [146] Hull, R.L., Westermark, G.T., Westermark, P., Kahn, S.E., Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:8 (2004), 3629–3643.
147. [147] Kapurniotu, A., Schmauder, A., Tenidis, K., Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. J Mol Biol 315:3 (2002), 339–350.
148. [148] Gotz, J., Lim, Y.-A., Eckert, A., Lessons from two prevalent amyloidoses—what amylin and Aβ have in common. Front Aging Neurosci 5:38 (2013), 1–9.
149. [149] Mayer, A.-P.T., Durward, A., Turner, C., Skellett, S., Dalton, N., Tibby, S.M., et al. Amylin is associated with delayed gastric emptying in critically ill children. Intensive Care Med 28:3 (2002), 336–340.
150. [150] Fu, W., Ruangkittisakul, A., MacTavish, D., Shi, J.Y., Ballanyi, K., Jhamandas, J.H., Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 287:22 (2012), 18820–18830.
151. [151] Zhang, Z., Hartmann, H., Do, V.M., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395:6703 (1998), 698–702.
152. [152] Fraser, P.E., Yang, D.-S., Yu, G., Lévesque, L., Nishimura, M., Arawaka, S., et al. Presenilin structure, function and role in Alzheimer disease. Biochim Biophys Acta (BBA) - Mol Basis Dis 1502:1 (2000), 1–15.
153. [153] Fox, A., Snollaerts, T., Errecart Casanova, C., Calciano, A., Nogaj, L.A., Moffet, D.A., Selection for nonamyloidogenic mutants of islet amyloid polypeptide (IAPP) identifies an extended region for amyloidogenicity. Biochemistry 49:36 (2010), 7783–7789.
154. [154] Janes, S., Gaeta, L., Beaumont, K., Beeley, K., Rink, T., The selection of pramlintide for clinical evaluation. Diabetes, 45(Suppl. 2), 1996, 235A.
155. [155] Young, A.A., Vine, W., Gedulin, B.R., Pittner, R., Janes, S., Gaeta, L.S., et al. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 37:4 (1996), 231–248.
156. [156] Hollander, P.A., Levy, P., Fineman, M.S., Maggs, D.G., Shen, L.Z., Strobel, S.A., et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes a 1-year randomized controlled trial. Diabetes Care 26:3 (2003), 784–790.
157. [157] Schubert, D., Behl, C., Lesley, R., Brack, A., Dargusch, R., Sagara, Y., et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci 92:6 (1995), 1989–1993.
158. [158] Maguschak, K.A., Ressler, K.J., β-catenin is required for memory consolidation. Nat Neurosci 11:11 (2008), 1319–1326.
159. [159] Adler, B.L., Yarchoan, M., Hwang, H.M., Louneva, N., Blair, J.A., Palm, R., et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 35:4 (2014), 793–801.
160. [160] Ceriello, A., Piconi, L., Quagliaro, L., Wang, Y., Schnabel, C.A., Ruggles, J.A., et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 28:3 (2005), 632–637.
161. [161] Meakin, P.J., Harper, A.J., Hamilton, D.L., Gallagher, J., McNeilly, A.D., Burgess, L.A., et al. Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 441:1 (2012), 285–296.
162. [162] Plucinska, K., Dekeryte, R., Koss, D., Shearer, K., Mody, N., Whitfield, P.D., et al. Neuronal human BACE1 knockin induces systemic diabetes in mice. Diabetologia 59:7 (2016), 1513–1523.